Humacyte, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 25.11 million compared to USD 3.72 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.04 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.42 USD | +17.15% | +39.26% | +126.06% |
May. 10 | Transcript : Humacyte, Inc., Q1 2024 Earnings Call, May 10, 2024 | |
Mar. 28 | Transcript : Humacyte, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+126.06% | 765M | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+46.96% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- HUMA Stock
- News Humacyte, Inc.
- Humacyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023